Related Experiment Video
Updated: Mar 29, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and
Vittorio Calderone1, Javier Gallego2, Gonzalo Fernandez-Miranda1
1Program of Molecular Medicine, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Background & Aims:
Vascular endothelial growth factor (VEGF) regulates angiogenesis, yet therapeutic strategies to disrupt VEGF signaling can interfere with physiologic angiogenesis. In a search for ways to inhibit pathologic production or activities of VEGF without affecting its normal production or functions, we investigated the post-transcriptional regulation of VEGF by the cytoplasmic polyadenylation element-binding proteins CPEB1 and CPEB4 during development of portal hypertension and liver disease.
Methods:
We obtained transjugular liver biopsies from patients with hepatitis C virus-associated cirrhosis or liver tissues removed during transplantation; healthy human liver tissue was obtained from a commercial source (control). We also performed experiments with male Sprague-Dawley rats and CPEB-deficient mice (C57BL6 or mixed C57BL6/129 background) and their wild-type littermates. Secondary biliary cirrhosis was induced in rats by bile duct ligation, and portal hypertension was induced by partial portal vein ligation. Liver and mesenteric tissues were collected and analyzed in angiogenesis, reverse transcription polymerase chain reaction, polyA tail, 3' rapid amplification of complementary DNA ends, Southern blot, immunoblot, histologic, immunohistochemical, immunofluorescence, and confocal microscopy assays. CPEB was knocked down with small interfering RNAs in H5V endothelial cells, and translation of luciferase reporters constructs was assessed.
Results:
Activation of CPEB1 promoted alternative nuclear processing within noncoding 3'-untranslated regions of VEGF and CPEB4 messenger RNAs in H5V cells, resulting in deletion of translation repressor elements. The subsequent overexpression of CPEB4 promoted cytoplasmic polyadenylation of VEGF messenger RNA, increasing its translation; the high levels of VEGF produced by these cells led to their formation of tubular structures in Matrigel assays. We observed increased levels of CPEB1 and CPEB4 in cirrhotic liver tissues from patients, compared with control tissue, as well as in livers and mesenteries of rats and mice with cirrhosis or/and portal hypertension. Mice with knockdown of CPEB1 or CPEB4 did not overexpress VEGF or have signs of mesenteric neovascularization, and developed less-severe forms of portal hypertension after portal vein ligation.
Conclusions:
We identified a mechanism of VEGF overexpression in liver and mesentery that promotes pathologic, but not physiologic, angiogenesis, via sequential and nonredundant functions of CPEB1 and CPEB4. Regulation of CPEB4 by CPEB1 and the CPEB4 autoamplification loop induces pathologic angiogenesis. Strategies to block the activities of CPEBs might be developed to treat chronic liver and other angiogenesis-dependent diseases.
Insights
Cytoplasmic polyadenylation element-binding proteins (CPEB1 and CPEB4) drive pathologic angiogenesis in liver disease by increasing vascular endothelial growth factor (VEGF) production. Targeting CPEBs may offer new treatments for liver and other angiogenesis-dependent diseases.
Area of Science:
- Molecular Biology
- Cell Biology
- Gastroenterology
Background:
- Vascular endothelial growth factor (VEGF) is crucial for angiogenesis, but its therapeutic inhibition can harm normal blood vessel formation.
- Investigating post-transcriptional regulation of VEGF is key to targeting pathologic angiogenesis without affecting physiological processes.
- Cytoplasmic polyadenylation element-binding proteins (CPEB1 and CPEB4) are explored for their role in VEGF regulation.
Purpose of the Study:
- To investigate the post-transcriptional regulation of VEGF by CPEB1 and CPEB4 in the context of liver disease and portal hypertension.
- To identify mechanisms of VEGF overexpression that specifically promote pathologic angiogenesis.
- To explore potential therapeutic targets for inhibiting aberrant angiogenesis in liver diseases.
Main Methods:
- Analysis of liver biopsies from patients with cirrhosis and healthy controls, alongside experiments in rats and CPEB-deficient mice.
- Induction of cirrhosis and portal hypertension in animal models.
- Techniques included angiogenesis assays, molecular analyses (RT-PCR, 3' RAPA, Southern blot, immunoblot), and microscopy (histology, immunohistochemistry, immunofluorescence).
Main Results:
- CPEB1 activation led to processing of VEGF and CPEB4 mRNAs, enabling CPEB4 overexpression.
- CPEB4 promoted VEGF mRNA cytoplasmic polyadenylation and translation, inducing VEGF-driven angiogenesis in vitro.
- Increased CPEB1 and CPEB4 levels were observed in cirrhotic human and animal livers; their knockdown reduced VEGF overexpression and portal hypertension severity.
Conclusions:
- A sequential mechanism involving CPEB1 and CPEB4 drives pathologic angiogenesis in liver and mesentery via VEGF overexpression.
- The CPEB1-CPEB4 pathway, including a CPEB4 autoamplification loop, is critical for inducing pathological angiogenesis.
- Targeting CPEB proteins presents a potential therapeutic strategy for chronic liver diseases and other conditions dependent on pathological angiogenesis.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Cell Specific Gene Expression
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Mechanism of Angiogenesis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

